Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Deshka S. Foster

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8372-4722; OpenAlex author ID A5021739455; NIH RePORTER profile ID 14825570. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
25
Papers, trials and grants by year

2020: 1 paper, 1 grant · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 7

  1. NFAT mediates pro-tumorigenic inflammation in cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.116849↗
  2. Protocol for orthotopic implantation of a collagen hydrogel to model pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1016/j.xpro.2025.104337↗
  3. Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.116347↗
  4. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  5. Hematoxylin and Eosin Architecture Uncovers Clinically Divergent Niches in Pancreatic Cancer. Co-author DOI 10.1089/ten.tea.2024.0039↗
  6. Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2023.101248↗
  7. Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment. First author DOI 10.3390/cancers12051347↗

Grants 1

  1. CANCER ASSOCIATED FIBROBLAST CLONALITY, CHROMATIN ACCESSIBILITY AND THERAPEUTIC TARGETING IN PANCREATIC DUCTAL ADENOCARCINOMA STROMA F32CA239312↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Thornton Longaker · 6 shared papers, 2020–2026 · strength 1.12
  2. Daniel Delitto · 5 shared papers, 2023–2026 · strength 0.97
  3. Jeffrey Allen Norton · 5 shared papers, 2020–2026 · strength 0.85
  4. Jason L. Guo · 4 shared papers, 2023–2026 · strength 0.70
  5. Maria Moozhiyil Korah · 3 shared papers, 2025–2026 · strength 0.66
  6. James Paul Agolia · 3 shared papers, 2025–2026 · strength 0.66
  7. Chuner Guo · 3 shared papers, 2025–2026 · strength 0.66
  8. George A. Poultsides · 2 shared papers, 2025–2026 · strength 0.39
  9. Brendan Christopher Visser · 2 shared papers, 2025–2026 · strength 0.39
  10. Shamik Mascharak · 2 shared papers, 2023–2024 · strength 0.31
  11. Teri A. Longacre · 2 shared papers, 2023–2024 · strength 0.31
  12. Vinod P. Balachandran · 1 shared paper, 2025 · strength 0.23
  13. Marsha Reyngold · 1 shared paper, 2025 · strength 0.23
  14. Kevin C. Soares · 1 shared paper, 2025 · strength 0.23
  15. T. Peter Kingham · 1 shared paper, 2025 · strength 0.23
  16. Michael Ian D'Angelica · 1 shared paper, 2025 · strength 0.23
  17. Joshua S. Jolissaint · 1 shared paper, 2025 · strength 0.23
  18. Jeffrey A. Drebin · 1 shared paper, 2025 · strength 0.23
  19. William R. Jarnagin · 1 shared paper, 2025 · strength 0.23
  20. Christopher H. Crane · 1 shared paper, 2025 · strength 0.23
  21. Alice Chia-Chi Wei · 1 shared paper, 2025 · strength 0.23
  22. Alex B. Blair · 1 shared paper, 2025 · strength 0.23
  23. Annah Grace Morgan · 1 shared paper, 2026 · strength 0.22
  24. Byrne Lee · 1 shared paper, 2025 · strength 0.17
  25. Amanda Kirane · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.